PANACEA BIOTEC LTD. - 531349 - Standalone And Consolidated Unaudited Financial Results (Provisional) Along With Limited Review Report For The Quarter And Nine Months Ended December 31, 2023
Unaudited financial results for quarter and nine months ended December 31, 2023 are enclosed herewith as Annexure -A PANACEA BIOTEC LTD. - 531349 - Board Meeting Outcome for Outcome Of Board Meeting
1. Standalone and Consolidated Unaudited Financial Results (Provisional) along with Limited Review Report for the quarter and nine months ended December 31, 2023 2. Re-appointment of Mr. Bhupinder Singh as a Non-Executive Independent Director 3. Appointment of Mrs. Ambika Sharma as an additional director in the capacity of Non-Executive Independent Director PANACEA BIOTEC LTD. - 531349 - Details Of Shares Dematerialized During January, 2024 Under Regulation 74(5) Of The SEBI (Depositories And Participants) Regulations, 2018
We are enclosing herewith the data of shares dematerialised during January, 2024
Panacea Biotec shares trade flat after USFDA classifies Baddi facility as OAI
A meeting of the board of directors of the company is scheduled to be held on February 13 to consider and approve the unaudited financial results. PANACEA BIOTEC LTD. - 531349 - Update On The USFDA Inspection Of The Company'S Material Wholly-Owned Subsidiary, Panacea Biotec Pharma Limited'S Facility At Baddi, Himachal Pradesh, India
Panacea Biotec Pharma Limited has now received a communication from the USFDA on January 31, 2024 indicating the inspection classification as "Official Action Indicated". PANACEA BIOTEC LTD. - 531349 - Board Meeting Intimation for For Approving The Standalone And Consolidated Unaudited Financial Results (Provisional) For The Quarter And Nine Months Ended December 31, 2023
PANACEA BIOTEC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2024 ,inter alia, to consider and approve the Standalone and Consolidated Unaudited Financial Results (Provisional) for the quarter and nine months ended December 31, 2023. The trading window of the Company shall remain closed for all Designated Persons of the Company till February 15, 2024 and the same will re-open from February 16, 2024 PANACEA BIOTEC LTD. - 531349 - Details Of Shares Dematerialised During The Month Of December, 2023 Under Regulation 74(5) Of The SEBI (Depositories And Participants) Regulations, 2018
We are enclosing herewith the data of shares dematerialized during the month of December, 2023 PANACEA BIOTEC LTD. - 531349 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are enclosing herewith a certificate dated January 02, 2024, issued by Skyline Financial Services Pvt. Ltd. confirming compliance under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2023. PANACEA BIOTEC LTD. - 531349 - Closure of Trading Window
We would like to inform that the trading window of the Company shall remain closed for all the Designated persons of the Company from January 01, 2024 till completion of 48 hours from the announcement of the Unaudited financial results of the Company for the quarter and nine months ended December 31, 2023 to the Stock Exchanges. Panacea Biotec shares rise 5% on pentavalent vaccine launch in India
EasyFourPol is the world's first fully liquid wP-IPV Pentavalent vaccine, which protects children against five deadly diseases i.e. Diphtheria, Tetanus, Pertussis, Polio, and invasive infections caused by Haemophilus Influenza Type b.